FY2025 · ended Dec 31, 2025 · Revenue $4.66B, +15.6% YoY · Filed Feb 12, 2026
Dexcom, Inc. (DXCM) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.7 billion and net income of $836.3 million. Free cash flow was $1.1 billion. As of Sep 30, 2026 it held $1.2 billion in cash and investments and $149.2 million in total debt.
Revenue (TTM)
$5.10B
+13.0% vs year-ago TTM
Net income (TTM)
$991.00M
+37.5% vs year-ago TTM
Operating cash flow (TTM)
$1.41B
-2.3% vs year-ago TTM
Free cash flow (TTM)
$1.10B
+3.4% vs year-ago TTM
EPS (TTM)
$2.53
+43.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
384.86M
-1.5% vs prior year
Net cash
$1.03B
as of Sep 30, 2026
Operating margin
24.0%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- DXCM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1093557
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Fresenius SE & Co. KGaA FSNUY
- West Pharmaceutical Services Inc WST
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B |
| Operating income | $911.8M | $600.0M | $597.7M | $391.2M | $265.8M |
| Net income | $836.3M | $576.2M | $541.5M | $341.2M | $216.9M |
| Diluted EPS | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 |
| Operating cash flow | $1.4B | $989.5M | $748.5M | $669.5M | $442.5M |
| Free cash flow | $1.1B | $630.7M | $511.9M | $304.7M | $53.3M |
| Total assets | $6.3B | $6.5B | $6.3B | $5.4B | $4.9B |
| Total liabilities | $3.6B | $4.4B | $4.2B | $3.3B | $2.9B |
| Stockholders' equity | $2.7B | $2.1B | $2.1B | $2.1B | $2.0B |
| Cash and investments | $1.1B | $2.5B | $2.8B | $2.5B | $2.7B |
| Total debt | $155.5M | $152.4M | $164.5M | $178.9M | $179.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 10, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
All 1000 Dexcom, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.